US FDA Aims For 'Appropriate Balance' For Resuming Inspections Suspended By Pandemic
Executive Summary
Phased approach will prioritize the safety of FDA and industry employees while striking ‘an appropriate balance between a scaled-back surveillance inspection program and the continuation of providing robust regulatory oversight,’ Commissioner Hahn says in a memo from self-isolation.
You may also be interested in...
US FDA Suspends Domestic Inspections As Staff Work Remotely In Covid-19 Response
Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent Covid-19, the disease caused by the virus, and breakthrough products such as cancer treatments.
COVID-19 Funds Flow To Startup In Bid To Restore US Pharmaceutical Manufacturing
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.
Continuous Manufacturing Back In Second Act
House tries again to promote advanced technology for the return of pharmaceutical manufacturing to the US in post-COVID-19 era.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: